1,3,5 and 1,2,4-triazines as Potent Scaffolds for Molecules Potentially Attenuating Breast Cancer Cell Lines

Author:

Dubey Pragya1,Pathak Dharam Pal1,Ali Faraat23ORCID,Chauhan Garima1

Affiliation:

1. Department of Pharmaceutical Chemistry, Delhi Institute of Pharmaceutical Sciences and Research, Mehrauli-Badarpur Road, Sector 3, Pushp Vihar, New Delhi, Delhi, 110017, India

2. Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, Hradec Králové, 500 05, Czech Republic

3. Department of Inspection and Enforcement, Laboratory Services, Botswana Medicines Regulatory Authority, Gaborone, Botswana

Abstract

Abstract: Breast cancer was diagnosed in around 2.3 million women in 2020. Owing to the alarming rise in the incidence of breast cancer, newer small molecules with targeted therapy are the need of the hour. A plethora of small molecules has been approved by the USFDA in the past few years. Triazine is a six-membered aromatic nitrogen heterocyclic molecule that was investigated for its various types of biological activities specially anticancer activity. Triazines are studied in many derivatives having remarkable anti-tumor activity as reported in this literature. Triazines are reported to possess a variety of biological activities and have been widely investigated as a scaffold for developing newer anti-tumor agents with an ability to inhibit various types of cancers, including breast cancers. Triazine derivatives show anticancer activity by inhibiting various targets like mTOR- kinase, PIP3-kinase, epidermal growth factor, etc. A limited number of triazine derivatives have also been clinically used for the treatment of breast cancer. A detailed study of the literature available on various derivatives of triazines with primary applicability as cytotoxic to breast cancer cell was carried out and is presented in this review. A total of 66 structurally diverse triazines have been reported in this review along with the structural features responsible for activity against various breast cancer cell lines. The primary amino residues to which the triazine based molecules bind in the estrogen receptor alpha and epidermal growth factor receptor 2, as found in various docking studies have also been detailed in the review. Abstract: Breast cancer was diagnosed in around 2.3 million women in 2020. Owing to the alarming rise in the incidence of breast cancer, newer small molecules with targeted therapy are the need of the hour. A plethora of small molecules has been approved by the USFDA in the past few years. Triazine is a six-membered aromatic nitrogen heterocyclic molecule that was investigated for its various types of biological activities specially anticancer activity. Triazines are studied in many derivatives having remarkable anti-tumor activity as reported in this literature. Triazines are reported to possess a variety of biological activities and have been widely investigated as a scaffold for developing newer anti-tumor agents with an ability to inhibit various types of cancers, including breast cancers. Triazine derivatives show anticancer activity by inhibiting various targets like mTOR- kinase, PIP3-kinase, epidermal growth factor, etc. A limited number of triazine derivatives have also been clinically used for the treatment of breast cancer. A detailed study of the literature available on various derivatives of triazines with primary applicability as cytotoxic to breast cancer cell was carried out and is presented in this review. A total of 66 structurally diverse triazines have been reported in this review along with the structural features responsible for activity against various breast cancer cell lines. The primary amino residues to which the triazine based molecules bind in the estrogen receptor alpha and epidermal growth factor receptor 2, as found in various docking studies have also been detailed in the review.

Publisher

Bentham Science Publishers Ltd.

Subject

Organic Chemistry

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3